NKGen Biotech, Inc.
NKGN
$0.02
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.87% | 66.23% | 74.32% | 68.76% | 83.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.34% | 17.79% | 22.40% | 21.61% | 21.80% |
| Operating Income | 9.34% | -17.79% | -22.42% | -21.80% | -22.18% |
| Income Before Tax | 46.67% | 13.89% | -196.08% | -180.60% | -210.12% |
| Income Tax Expenses | 657.14% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | 46.61% | 13.89% | -196.03% | -180.56% | -210.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.61% | 13.89% | -196.03% | -180.56% | -210.06% |
| EBIT | 9.34% | -17.79% | -22.42% | -21.80% | -22.18% |
| EBITDA | 9.66% | -18.72% | -23.59% | -22.97% | -23.37% |
| EPS Basic | 72.90% | 51.55% | -52.60% | -56.81% | -78.94% |
| Normalized Basic EPS | 48.58% | 51.05% | -33.33% | -15.45% | -36.11% |
| EPS Diluted | 71.46% | 49.95% | -52.60% | -56.81% | -78.94% |
| Normalized Diluted EPS | 51.21% | 53.41% | -33.33% | -15.45% | -36.11% |
| Average Basic Shares Outstanding | 86.72% | 103.76% | 101.67% | 69.95% | 45.14% |
| Average Diluted Shares Outstanding | 106.49% | 129.41% | 101.67% | 69.95% | 45.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |